Anuradha Bhattacharyya

Company: PTC Therapeutics

Job title: Executive Director Biology & NRD

Seminars:

Live Q&A & Panel Discussion: The Value of Splicing Modulators for Therapeutics & Future Applications 4:50 pm

Targeting RNA splicing for disease application intervention has proven a valuable therapeutic intervention. It is now essential to review the clinical landscape of successes which exists with targeting the RNA spliceosome, consider various approaches and motifs being harnessed to target diseases beyond SMA and review future applicability of this modality.Read more

day: Day One

Discovery & Development of PTC518, a Selective Huntingtin Lowering Splicing Modifier for the Treatment of Huntington’s Disease 4:00 pm

Initiated Huntingtin lowering drug discovery program – Identified splicing modifiers and deciphered the mechanism of HTT lowering Lead optimization efforts led to the discovery of PTC518 PTC518 data to be shared, demonstrating HTT lowering in cells and animals; POC demonstrated in humansRead more

day: Day One